Company Active LTD

Company profile

Ascend Technologies Limited

Ascend Technologies Limited

Ascend Technologies Limited is a UK company with status active founded in 2013 based in South East England.

CRN
08700928
Founded
2013
Age
12

Overview

Legal name
ASCEND TECHNOLOGIES LIMITED
Region
South East England
Registered address
CUMBERLAND HOUSE
CUMBERLAND PLACE
SOUTHAMPTON
ENGLAND
SO15 2BG
Insolvency history
No

Latest accounts

Financial period: 1 Oct 2023 to 30 Sep 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
2

Company events

Reference milestones and recent Companies House filing stream events.

6 events
07 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Jun
2026

Accounts due

Accounts Due

Next accounts due date

23 Sep
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Sep
2024

Accounts filed

Accounts

Last accounts made up date

25 Sep
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzNzE4MTUxNWFkaXF6a2N4

Published 25 Sep 2024 11:11

23 Sep
2013

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2023
Funded years
2023, 2024
Age at first award
9 years

Projects

2024 EU-Funded Lead participant

Advanced nano encapsulation of bio-based pesticides and fertilisers for a circular and sustainable viticulture

1 Jun 2024 to 31 May 2028

Awarded
£478,331
Total cost £478,331

The main objective of the VINNY is the development of sustainable, low-cost nanoformulated biopesticides (nanoBPs) and biofertilizers (nanoBFs) for contributing to more resilient vineyard systems. The application of VINNY nanoformulations will allow contributing to the ultimate switch from intensive to sustainable agriculture in viticulture, on a global s...

2023 EU-Funded Lead participant

Photoacoustic imaging and artificial intelligence-based theranostic approach for cancer

1 Sep 2023 to 31 Aug 2026

Awarded
£327,046
Total cost £327,046

Health programs crave for diagnostic imaging and eradication of chemoresistant neoplastic lesions smaller than 1 mm of size. PHIRE, based on the outcomes from EDIT (FET-OPEN-RIA, GA#801126), aims at bringing closer to market a novel high-resolution theranostic medical device effective in the clinical applications for lesions <1 mm, ready for application i...

Product types

EU-Funded